Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with CrossoverCélèste Lebbé, Brigitte Dréno, Joseph Kerger et al.|Cancers|2020Cited by 47